| Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... New England Journal of Medicine 375 (19), 1823-1833, 2016 | 10035 | 2016 |
| Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ... New England Journal of Medicine 373 (2), 123-135, 2015 | 9165 | 2015 |
| Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer L Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban, E Felip, ... New England journal of medicine 378 (22), 2078-2092, 2018 | 6151 | 2018 |
| Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC MA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ... New England Journal of Medicine 378 (24), 2288-2301, 2018 | 3601 | 2018 |
| Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden MD Hellmann, TE Ciuleanu, A Pluzanski, JS Lee, GA Otterson, ... New England Journal of Medicine 378 (22), 2093-2104, 2018 | 3075 | 2018 |
| First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer L Horn, AS Mansfield, A Szczęsna, L Havel, M Krzakowski, MJ Hochmair, ... New England Journal of Medicine 379 (23), 2220-2229, 2018 | 3059 | 2018 |
| Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... New England Journal of Medicine 379 (24), 2342-2350, 2018 | 2781 | 2018 |
| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2614 | 2017 |
| Nivolumab plus ipilimumab in advanced non–small-cell lung cancer MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, ... New England Journal of Medicine 381 (21), 2020-2031, 2019 | 2482 | 2019 |
| Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up D Planchard, ST Popat, K Kerr, S Novello, EF Smit, C Faivre-Finn, TS Mok, ... Annals of Oncology 29, iv192-iv237, 2018 | 2299 | 2018 |
| Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer: AVAiL M Reck, J von Pawel, P Zatloukal, R Ramlau, V Gorbounova, V Hirsh, ... Journal of Clinical Oncology 27 (8), 1227-1234, 2009 | 1968 | 2009 |
| Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial ES Kim, V Hirsh, T Mok, MA Socinski, R Gervais, YL Wu, LY Li, ... The Lancet 372 (9652), 1809-1818, 2008 | 1760 | 2008 |
| Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater M Reck, D Rodríguez–Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... Journal of Clinical Oncology 37 (7), 537-546, 2019 | 1528 | 2019 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy … EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel, ... The Lancet 384 (9944), 665-673, 2014 | 1462 | 2014 |
| Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind … TJ Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, ... Journal of clinical oncology 30 (17), 2046-2054, 2012 | 1228 | 2012 |
| First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open … L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ... The Lancet Oncology 22 (2), 198-211, 2021 | 1144 | 2021 |
| Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised … M Reck, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, ... The lancet oncology 15 (2), 143-155, 2014 | 1125 | 2014 |
| Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up S Novello, F Barlesi, R Califano, T Cufer, S Ekman, MG Levra, K Kerr, ... Annals of Oncology 27, v1-v27, 2016 | 1013 | 2016 |
| Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer S Gadgeel, D Rodríguez-Abreu, G Speranza, E Esteban, E Felip, ... Journal of clinical oncology 38 (14), 1505-1517, 2020 | 1012 | 2020 |
| Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in … M Reck, TSK Mok, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, ... The Lancet Respiratory Medicine 7 (5), 387-401, 2019 | 929 | 2019 |
